This study is a prospective, single-arm, phase II clinical trial designed to evaluate the safety and efficacy of PD-L1 monoclonal antibody combined with chemoradiotherapy as a bridge to liver transplantation in patients with locally advanced unresectable perihilar cholangiocarcinoma (pCCA).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Transplant Completion Rate, TCR
Timeframe: From the date of randomization until the date of first documented disease progression or the date of death from any cause, whichever occurs first, with an assessment period of up to 48 months.